Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction.

Détails

ID Serval
serval:BIB_5CF0C4E919FE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction.
Périodique
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
Auteur(s)
Pilgrim T., Piccolo R., Heg D., Roffi M., Tüller D., Vuilliomenet A., Muller O., Cook S., Weilenmann D., Kaiser C., Jamshidi P., Khattab A.A., Taniwaki M., Rigamonti F., Nietlispach F., Blöchlinger S., Wenaweser P., Jüni P., Windecker S.
ISSN
1969-6213 (Electronic)
ISSN-L
1774-024X
Statut éditorial
Publié
Date de publication
10/12/2016
Peer-reviewed
Oui
Volume
12
Numéro
11
Pages
e1343-e1354
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Our aim was to compare the safety and efficacy of a novel, ultrathin strut, biodegradable polymer sirolimus-eluting stent (BP-SES) with a thin strut, durable polymer everolimus-eluting stent (DP-EES) in a pre-specified subgroup of patients with acute ST-segment elevation myocardial infarction (STEMI) enrolled in the BIOSCIENCE trial.
The BIOSCIENCE trial is an investigator-initiated, single-blind, multicentre, randomised non-inferiority trial (NCT01443104). Randomisation was stratified according to the presence or absence of STEMI. The primary endpoint, target lesion failure (TLF), is a composite of cardiac death, target vessel myocardial infarction, and clinically indicated target lesion revascularisation within 12 months. Between February 2012 and May 2013, 407 STEMI patients were randomly assigned to treatment with BP-SES or DP-EES. At one year, TLF occurred in seven (3.4%) patients treated with BP-SES and 17 (8.8%) patients treated with DP-EES (RR 0.38, 95% CI: 0.16-0.91, p=0.024). Rates of cardiac death were 1.5% in the BP-SES group and 4.7% in the DP-EES group (RR 0.31, 95% CI: 0.08-1.14, p=0.062); rates of target vessel myocardial infarction were 0.5% and 2.6% (RR 0.18, 95% CI: 0.02-1.57, p=0.082), respectively, and rates of clinically indicated target lesion revascularisation were 1.5% in the BP-SES group versus 2.1% in the DP-EES group (RR 0.69, 95% CI: 0.16-3.10, p=0.631). There was no difference in the risk of definite stent thrombosis.
In this pre-specified subgroup analysis, BP-SES was associated with a lower rate of target lesion failure at one year compared to DP-EES in STEMI patients. These findings require confirmation in a dedicated STEMI trial.

Pubmed
Web of science
Création de la notice
29/05/2017 19:13
Dernière modification de la notice
20/08/2019 15:15
Données d'usage